Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
life sciences
national blog main
new york top stories
10
×
new york blog main
national top stories
san francisco top stories
boston blog main
boston top stories
clinical trials
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
amgen
europe top stories
novartis
cancer
europe blog main
alirocumab
alnylam pharmaceuticals
boehringer ingelheim
deals
diagnostics
eli lilly
What
drug
10
×
fda
new
patients
approval
approved
bio
brings
cholesterol
friday
market
medicine
oral
plan
roundup
therapy
type
wave
acquire
acquisitions
activity
advantages
agency
agreed
aimmune
allergy
anathema
atrophy
awaited
awarded
bar
bid
biggest
billion
biotech
boehringer
build
buy
cancer
cash
Language
unset
10
×
Current search:
drug
×
biotech
×
unset
×
" new york top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs